Why has ASX 200 healthcare stock Imugene leapt 15% in a month?

Let's check what's been going on with this biotechnology company lately.

| More on:
Two laboratory researchers in white coats and gloves sit side by side with scientific equipment and a computer screen conducting medical related research.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • This ASX 200 healthcare stock has soared almost 15% in a month 
  • An update on a clinical trial appeared to give the share price a boost 
  • The company is developing immunotherapies to treat cancer 

The Imugene Ltd (ASX: IMU) share price has been racing ahead in the last month.

Shares in the ASX 200 healthcare stock have risen 14.6% since market close on 17 March and are currently fetching 13.75 cents a share. For perspective, the S&P/ASX 200 Health Care Index (ASX: XHJ) has climbed nearly 5% in this same time frame. Though Imugene shares are sliding 1.79% today.

Let's take a look at what's been impacting this ASX 200 healthcare stock lately.

Why has the Imugene share price been rising?

Imugene is a biotechnology company developing therapies that activate the immune system to target cancer tumours.

A notable highlight during the month was an update on its Vaxinia MAST (metastatic advanced solid tumours) trial.

Imugene shares soared nearly 8% on the day of the announcement and a further 7% the following day.

The first patients in cohort three have been dosed in the monotherapy intratumoral (IT) and intravenous (IV) arms of the trial.

The study, together with the City of Hope in the US, is investigating the safety of novel cancer-killing virus CF33-hNIS.

Commenting on this news, CEO and managing director Leslie Chong said:

Still being less than 12 months since the very first patients were dosed, we're now well advanced on amassing the critical data we require to publish on the outcomes of this study, and we remain very positive on the potential benefit to patients.

Imugene said the trial remains on schedule and is expected to take 24 months overall, having commenced in May.

Meanwhile, in late March, Imugene updated the market with a presentation at the NWR healthcare conference.

Imugene noted its investment highlights including "five unique assets" – HER-Vaxx, CHECKvacc, CF33-CD19, Vaxinia, and PD1-Vaxx – targeting multiple potential platform targets.

The company also has three platform technologies, three scientific collaborations, and two supply agreements with Merck/KGaA/Pfizer and Roche.

Share price snapshot

Despite its recent gains, the Imugene share price remains 36% lower over the past 12 months. It has also dropped 8% in just the last week.

This ASX 200 healthcare stock has a market capitalisation of about $883 million based on the latest share price.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »